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values were greater than the respective median. The difference
in treatment effect on baseline disease severity sub-group was
analyzed using analysis of covariance (ANCOVA).
Results: In total, 3235 patients comprised the ITT population of
the pooled efﬁcacy analysis. Out of these, 3214 patients were
included in the disease severity analysis [low (n = 923), medium
(n =1456) and high (n=835)]. Mean OA pain at baseline was 79
mm in the high disease severity, 65 mm in the medium disease
severity and 53 mm in the low disease severity subgroup. The
greatest reduction in OA pain intensity with lumiracoxib and
celecoxib compared to placebo, was seen in the highest disease
severity group (lumiracoxib [-9.30mm; p≤0.001] celecoxib [-6.70
mm; p=0.004]) as compared to the medium disease severity
group (lumiracoxib [-5.48; p≤0.001], celecoxib [-4.76; p=0.006])
and low disease severity group (lumiracoxib [-4.74 mm; p=0.012]
celecoxib [-4.74 mm; p=0.030]). Similar results were seen for
patient’s global assessment of disease activity and the functional
status, assessed by WOMAC™ LK3.1 total score (Table 1).
Conclusions: Lumiracoxib provides effective pain relief and im-
provement of symptoms in all subgroups of OA patients deﬁned
by disease severity at baseline. However, there is a trend for
greatest efﬁcacy in the subgroups of patients with highest dis-
ease severity.
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Purpose: Osteoarthritis (OA) is perceived as a major public
health problem, and today, various clinical outcome methods are
used to see the improvement of the management for this condi-
tion. The purpose of this study was to determine if self-reported
improvements in pain and function correlate with improvement in
objective measures of disease in OA.
Methods: Eighty female patients (mean age: 52.3 ± 8.7 years)
with bilateral OA of the knee were assessed by some tests includ-
ing [sociodemographics, body mass index (28.34± 4.88 kg/m2,
and a self-reported questionnaire-Western Ontario and McMas-
ter University Osteoarthritis Index (WOMAC) scores] and physi-
cal [muscular strength by ISOMED 2000 isokinetic dynamometry,
proprioception by determining deﬁcit at the knee joint using by
Functional Squat System, Timed Get up and Go (TGG) for walk-
ing duration, visual analog scale for measuring the intensity of
the present pain, warmth, effusion] and clinical examination of
the knees (Altman Grade II). Subjects received closed kinetic
chain in clinic and home-based structured exercise program 5
days a week for 4 weeks, totally 20 sessions. All tests were done
before and after the 4-week treatment period.
Results: There were no signiﬁcant correlation between pain at
rest and night, during activity and proprioception deﬁcit in left (r=
0.05, r= -0.16, and r= -0.14; p>0.05) and right (r=0.22, r=0.07,
and r=0.19; p>0.05) knee joint pre-treatment, respectively. Be-
sides; there were found a correlation after treatment between
pain at rest and night, with activity and proprioception deﬁcit in
left (r= 0.32, r= -0.37, and r= -0.29; p<0.05) and right (r=0.53,
r=0.39, and r=0.2; p<0.05) knee. The peak torque of isokinetic
muscular strength and proprioception of participants were im-
proved after rehabilitation. Of eighty eligible patients, WOMAC
scores were improved after immediate treatment in clinical-based
exercise group, 46.4% and 56.4% reported the improvement
in pain and function, respectively. However, improvements in
WOMAC scores were not associated with improvements in any
of the other measures (Left knee peak torque (PT), r= -0.28 and
right knee PT, r= -0.29; p>0.05 for all). There was a signiﬁcant
correlation between proprioception scores and TGG test either
before (r= -0.31; p=0.016) (p<0.05) or after (r= -0.4141; p=0.001)
(p<0.01) rehabilitation. The ﬁndings at 4th weeks after enroll-
ment were that the quadriceps strength was slightly increased
but the walking duration was decreased when compared with
the initial assessment. An exercise frequency of 20 sessions in
a month was sufﬁcient to improve muscle strength and walking
distance.
Conclusions: Seventy-three of participants reported signiﬁcant
improvements in WOMAC pain and disability after treatment.
Both closed kinetic chain and home-based exercise program
produce a signiﬁcant improvement in strength and walking ability,
especially in the ﬁrst months. In the assessment of knee OA,
muscle strength, proprioception, and walking ability can be used
to measure the effect of improvement of pain and disability after
treatment programs.
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Purpose: Results of studies that have evaluated obesity as a
risk factor for the progression of structural damage in knees with
osteoarthritis (OA) are conﬂicting. However, researchers who de-
sign clinical trials for structure-modifying drugs for OA (SMOADs)
often consider “weighting” the study cohort with patients with a
higher body mass index (BMI), in the hope of enriching for pa-
tients who will have more rapidly progressive OA. We asked
whether, among obese patients with knee OA, a higher BMI was
associated with an increased rate of joint space narrowing (JSN).
Methods: In 60 women with symptomatic OA (KLG2 or 3 in a
standing AP radiograph) and a mean BMI (± SD) of 37.2 ±
5.1, medial tibiofemoral JSN over 12 months were measured in
modiﬁed Lyon schuss (mLS) radiographs. We compared these
ﬁndings to those in 81 age-matched, non-obese, asymptomatic,
KLG0 women (BMI = 23.5 ± 2.3).
Results: Among the OA patients, a higher BMI tended to be
associated with a higher KLG. Mean BMI was 36.0 ± 4.5 in
KLG2 patients and 38.4 ± 5.4 in KLG3 patients (p=0.06). Mean
JSN in the 81 controls was 0.02 ± 0.25 mm (p=0.51), whereas
in the 30 KLG2 knees and 30 KLG3 knees, mean JSN was 0.12
± 0.31 mm (p=0.08 vs. KLG0) and 0.32 ± 0.50 mm (p<0.0001
vs. KLG0), respectively. KLG3 knees were more homogeneous
with respect to JSN than KLG2 knees (SRM = 0.64 vs. 0.39).
BMI was not related to JSN in OA knees.
Conclusions: Among these OA patients, with a BMI ≥ 30,
there was no evidence that progressively higher BMIs were
accompanied by a progressively increasing rate of JSN. We
will determine whether a longer period of observation will yield
different results. In the mLS views, 12 months was sufﬁcient to
detect JSN in KLG2/3 knees, relative to knees of nonarthritic
controls (p=0.0001). Because none of our OA patients had a
BMI <30, this study cannot not address the question whether
JSN is more rapid in overweight or obese subjects than in knee
OA patients of normal weight. For an SMOAD trial, these data
suggest that recruitment of patients with a BMI much beyond 30
will not enrich the sample in subjects who will exhibit more rapid
JSN than would patients with a BMI of 30.
